TIDMOXB

RNS Number : 1703L

Oxford Biomedica PLC

14 July 2017

Director/PDMR Share Dealings

Oxford, UK - 14 July 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 13 July 2017 Kyriacos Mitrophanous, Chief Scientific Officer, and his wife have exercised 1,499,484 share options at prices set out below and sold all of the resulting shares at 8.7p.

 
 Number of options   Exercise price 
         exercised              (p) 
------------------  --------------- 
         1,170,000              1.0 
------------------  --------------- 
            73,622             1.56 
------------------  --------------- 
            75,094             2.03 
------------------  --------------- 
            63,479             2.83 
------------------  --------------- 
            81,200              3.1 
------------------  --------------- 
            36,089              5.4 
------------------  ---------------

Following this transaction Dr Mitrophanous and his wife hold 7,453,956 options and 150,000 shares in the company. The issued share capital of the Company is 3,093,846,939 1p ordinary shares.

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: +44 (0)1865 
   John Dawson, Chief Executive              783 000 
   Officer 
   Tim Watts, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: +44 (0)20 3709 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Chris Welsh/Laura Thornton

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBUGDRUSBBGRS

(END) Dow Jones Newswires

July 14, 2017 11:49 ET (15:49 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Oxford Biomedica Charts.